Patient and provider perspectives are shared regarding available treatments, as well as how to manage treatment-related adverse events that can effect the quality of life for a patient diagnosed with cholangiocarcinoma.
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
EP. 9: Patient Perspective Regarding FGFRi Adverse Event Profiles
January 31st 2024A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.
EP. 14: Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma
February 14th 2024Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.
Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL
Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer
Dr Lheureux on Advancements in Targeted Treatment Delivery for Ovarian Cancer
Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies
2 Commerce Drive
Cranbury, NJ 08512